Neurotoxicity is a major side effect of platinum derivatives both during and after treatment. In the absence of effective pharmacological compounds, the opportunity to identify safe adjuvant treatments among medicinal plants seems appropriate. Astragali radix is an adaptogenic herbal product recently analyzed in platinum-treated cancer patients. With the aim of evaluating the anti-neuropathic profile of Astragali radix, a previously characterized aqueous (Aqu) and two hydroalcoholic (20%HA and 50%HA) extracts were tested in a rat model of oxaliplatin-induced neuropathy. Repeated administrations significantly reduced oxaliplatin-dependent hypersensitivity with 50%HA, the most effective, fully preventing mechanical and thermal hypersensitivity. Ex vivo, 50%HA reduced morphometric and molecular alterations induced by oxaliplatin in peripheral nerve and dorsal-root-ganglia. In the spinal cord and in brain areas, 50%HA significantly decreased activation of microglia and astrocytes. Furthermore, 50%HA prevented the nephro-and hepato-toxicity induced by the anticancer drug. The protective effect of 50%HA did not alter oxaliplatin-induced apoptosis in colon tumors of Pirc rats, an Apc-driven model of colon carcinogenesis. The hydroalcoholic extract (50%HA) of Astragali radix relieves pain and promotes the rescue mechanisms that protect nervous tissue from the damages triggering chronic pain. A safe profile strongly suggests the usefulness of this natural product in oxaliplatin-induced neuropathy.
. The 2014 practical clinical guideline from the American Society of Clinical Oncology states that there are no agents recommended for the prevention of chemotherapy-induced neuropathic pain 8 . No progress has been achieved up to now 9 . High-quality, consistent evidence is insufficient; the best available data support a moderate recommendation for treatment with duloxetine 10, 11 . Consequently, the prevention or treatment of oxaliplatin-induced neuropathy (as well as other chemotherapy induced neuropathies) is a relevant therapeutic need.
In this context, a scientific approach to the study of medicinal plants may help to identify adjuvant treatments able to reduce the side effects of chemotherapy. Phytotherapy is based on the combined action of a mixture of constituents able to offer a multiple approach to the multi-factorial nature of neuropathy pathogenesis. The
Results
Behavioral measurements. On day 21, oxaliplatin administration to Sprague-Dawley rats (2.4 mg kg −1 intraperitoneally -i.p. -daily, for 5 consecutive days/week for 3 weeks) altered the sensitivity to both noxious and non-noxious mechanical stimuli. As measured by the Paw pressure test, oxaliplatin treatment lowered the pain threshold in response to a mechanical noxious stimulus, reducing the control value from 66.5 ± 1.9 g to 40.7 ± 1.8 g (Fig. 1A ). The treatment with Aqu and 20%HA (300 mg kg −1 per os -p.o. -daily from the first day in which the chemotherapic compound was injected) reduced the pain behavioral alterations whereas 50%HA (300 mg kg −1 daily p.o. following the same protocol) fully prevented the sensitivity to noxious mechanical stimuli (Fig. 1A) .
The withdrawal threshold to a non-noxious mechanical stimulus, measured by the electronic Von Frey apparatus, was decreased in oxaliplatin-treated animals (day 21) from 23.7 ± 1.2 g, to 13.8 ± 0.9 g (Fig. 1B) . The pro-allodynic effect of oxaliplatin was significantly reduced by Aqu and totally prevented by both 20%HA and 50%HA (Fig. 1B) .
The response to a non-noxious thermal stimulus is shown in panel C of Fig. 1 . The anticancer agent decreased the licking latency in the Cold plate test from 24.1 ± 1.2 s (vehicle + vehicle) to 16.2 ± 0.8 s (oxaliplatin + vehicle). Administration of 50%HA was the only dose able to significantly reduce oxaliplatin-induced cold hypersensitivity (Fig. 1C) .
The above described treatments with Aqu, 20%HA and 50%HA performed on control rats (which did not receive oxaliplatin) did not alter the pain threshold evaluated using the Paw pressure, Von Frey and Cold plate tests (Fig. 1A ,B and C).
To better evaluate the pain relief profile of 50%HA, the extract was administered p.o. daily (subchronic; from the first day in which oxaliplatin was injected) at 3 different dosages, 30, 100 and 300 mg kg . On day 21, the pain threshold measurement by the Paw pressure test showed that 50%HA provided a dose-dependent protective effect after repeated treatment (Fig. 2, subchronic) . The full efficacy of 50%HA was shown also on day 14, suggesting early beneficial effects ( Supplementary Fig. S1 ). On the contrary, 300 mg kg −1 50%HA acutely administered p.o. on day 21 did not modify the pain threshold decreased by oxaliplatin (Fig. 2, acute) .
Once evaluated the activity of the phytocomplex 50%HA, we aimed to enquire the possible efficacy of single fractions of the crude extract. 50%HA was suspended in water and extracted with solvents with increasing polarity (dichloromethane, ethyl acetate, butanol, water). After liophylization we obtained solid products in the following percentage (compared to the quantity of the total extract): 1) dichloromethane fraction, 22%; 2) ethyl acetate fraction, 3%; 3) butanol fraction, 6%; 4) water fraction, 69%. Accordingly, different groups of animals were treated with dosages representing these percentages of the total extract dose (300 mg kg −1 ). In particular, 1) dichloromethane fraction, 66 mg kg −1 ; 2) ethyl acetate fraction, 9 mg kg −1 ; 3) butanol fraction, 18 mg kg −1 ; 4) water fraction, 207 mg kg −1 . These treatments were compared with effects due to the administration of the mixture of all fractions at the same doses. As shown in the Supplementary Fig. S2 , none of the single fractions induced a significant effect whereas the animals that received the co-administration of all the fractions showed a decrease of pain hypersensitivity comparable to that induced by the total crude extract.
Finally, oxaliplatin negatively influenced motor coordination. The Rota rod test measures the walking time and number of falls in 600 s from a rotating rod. Oxaliplatin-treated animals showed reduced walking time (197.8 ± 24.8 s; Supplementary Fig. S3A ) and an increased number of falls (4.4 ± 0.5; Supplementary Fig. S3B ) in comparison with control animals (600 s and 0.7 ± 0.3, respectively). Repeated administration of each Astragali radix extract (300 mg kg −1 daily p.o. starting from the first day of oxaliplatin injection) restored motor coordination, improved the time spent in equilibrium on the rod and reduced the number of falls ( Supplementary Fig. S3B ). In the absence of oxaliplatin, repeated treatment with Astragalus extracts did not alter motor coordination per se ( Supplementary Fig. S3A and B). p-NF-H expression in the sciatic nerve. Expression level evaluation of the phosphorylated form of the heavy polypeptide of neurofilament (p-NF-H, a major determinant of axonal structure and functionality 19 ) in the rat sciatic nerves showed an oxaliplatin-dependent down-regulation (Fig. 3A , oxaliplatin + vehicle) compared to the vehicle control group (Fig. 3A , vehicle + vehicle). Compared to the oxaliplatin group, nerve sections of 50%HA treated rats (Fig. 3A , vehicle + 50%HA) exhibited a p-NF-H increment. The immunolabeling observed in Scientific RepoRts | 7:42021 | DOI: 10.1038/srep42021 the presence of 50%HA alone (Fig. 3A , vehicle + 50%HA) did not show any significant difference in comparison to control (Fig. 3A , vehicle + vehicle).
Histology and morphometry of dorsal root ganglia (DRG).
The features of oxaliplatin-induced neuronopathy have already been reported in detail [19] [20] [21] . To summarize, the main pathological changes were found in the nucleolus and the nucleus of the DRG neuronal cells where an increased incidence of multinucleolated cells (Fig. 3B , black arrow in oxaliplatin + vehicle, and striped bar in upper histogram) and nucleolar segregation (Fig. 3B , black arrow in oxaliplatin + 50%HA, and striped bar in lower histogram) were evidenced. On the contrary, the neuronal cytoplasmic involvement was very limited. Quantitative analysis of the multinucleated nuclei (upper histogram) and eccentric nucleoli (lower histogram) in the presence of 50%HA was significantly reduced (Fig. 3B , oxaliplatin + 50%HA and gray bars) compared to oxaliplatin alone.
ATF-3 expression in L4-L5 DRG.
Expression of the activating transcription factor 3 (ATF-3) in DRG is considered a neuronal marker of nerve injury 22 . Immunohistochemistry was used to assess its expression in the presence or in the absence of 50%HA (Fig. 3C ). ATF-3-positive cells from 3 non-adjacent transverse sections (10 μ m) of L4 and L5 DRG per animal (n = 6 per group) were counted, and expressed as a percentage of the total number of cells counted in these sections. DRG neurons showed significant ATF-3 expression following oxaliplatin treatment (striped bar), whereas the presence of 50%HA (gray bar) displayed a significant reduction of ATF-3 nuclear immunoreactivity. No differences were observed following 50%HA treatment alone (white bar) Spinal and cerebral glial analysis. As we have previously reported 19 , a 3 week oxaliplatin treatment is associated with a numeric and morphological astrocyte boost within the spinal cord, where the increase in the cell body size denotes their typical activated state (Fig. 4A , oxaliplatin + vehicle, see insert for morphological details). On the contrary, microglia did not undergo any of the above modifications (data not shown). Treatment with 50%HA resulted in a numerical reduction of astrocytes within the dorsal horns as demonstrated by immunohistochemistry for the astrocytic marker Glial Fibrillary Acidic Protein (GFAP) (Fig. 4A , oxaliplatin + 50%HA). Rats that received only 50%HA (vehicle + 50%HA) were indistinguishable from control rats (vehicle + vehicle), showing no astrogliosis or morphological modifications.
Under the same conditions, we measured the density of astrocytes (GFAP) and microglia (by means of the Iba1 specific marker) in several brain areas known to be active during chronic pain 23, 24 and already demonstrated to be involved in cerebral gliosis following oxaliplatin-administration 19 . In all examined areas, our results demonstrated a 50%HA-dependent reduction in the density of both astrocytes and microglia ( Fig. 4B and C, gray bars, respectively) in comparison to oxaliplatin-treated rats (striped bars). Rats treated with only 50%HA did not exhibit any differences from control animals (data not shown).
Nrf2 and NQO1mRNA levels in the nervous system. To assess the redox profile after treatments, two major cellular antioxidant players were analyzed. Oxaliplatin treatment did not modify the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) mRNA either in the sciatic nerve or in the spinal cord ( Supplementary Fig. S4A and C) . On the contrary, Nrf2 increased in DRGs, 50%HA significantly prevented this alteration ( Supplementary Fig. S4B ). 50%HA decreased Nrf2 spinal levels (oxaliplatin + 50%HA) in comparison to control ( Supplementary Fig. S4C ). Similarly, 50%HA decreased the NAD(P)H dehydrogenase, quinone 1 (NQO1) (oxaliplatin + 50%HA) in DRGs in comparison to control ( Supplementary Fig. S4B ). Oxaliplatin reduced NQO1 levels in the spinal cord, 50%HA was not effective ( Supplementary Fig. S4C ).
Hepatic and renal histopathological features. Given the neuroprotective properties of 50%HA, we examined its potential protective effects against hepatic and renal toxicity induced by oxaliplatin treatment. The macroscopic liver appearance of the vehicle + vehicle-treated animals appeared normal without any alterations in terms of shape, dimension, hue or solidity (data not shown). The microscopic examination of liver sections from the control rats showed a normal lobular pattern, hepatic cells with well-preserved cytoplasm, prominent nucleus, nucleolus and a well-defined central vein. There was no sign of inflammation or fatty change (Fig. 5A , vehicle + vehicle). In animals administered with oxaliplatin alone, liver sections showed marked congested central veins and sinusoids, multifocal areas of necrosis, increased fatty deposits (insert in Fig. 5A , oxaliplatin + vehicle, black arrow) and the presence of inflammatory cells with granular swelling (insert in Fig. 5A , oxaliplatin + vehicle, black arrowhead). Treatment with 50%HA resulted in a considerable reduction in necrotic areas, with disappearance of inflammatory infiltrates and a remarkable improvement in the macrovesicular fatty changes of the hepatic parenchyma (Fig. 5A , oxaliplatin + 50%HA). Figure 5A (vehicle + 50%HA) shows that there was no sign of alterations in animals administered with 50%HA alone. Figure 5B (oxaliplatin + vehicle) shows representative hematoxylin-eosin stained sections demonstrating the glomerulopathy with cytopathic changes developed by oxaliplatin-treated kidney. In particular, glomerular alterations consisted of mesangial expansion ( The number of (B) GFAP-and (C) Iba-1-positive cells was evaluated in oxaliplatin-treated rats on day 21 analyzing the following areas: Cg1, cyngulate cortex area 1; S1, primary somatosensory cortex; M1, primary motor cortex; PAG, periaqueductal grey; mfb, medial forebrain bundle. Each value represents the mean ± SEM of 6 rats per group, performed in two different experimental sets. *P < 0.05 versus vehicle + vehicle; ^P < 0.05 versus oxaliplatin + vehicle. Apoptosis in tumors and normal mucosa of Pirc rats. To gather information on the possible interference of Astragalus with the toxic effect of oxaliplatin in colon tumors, we measured the level of apoptosis in tumors and normal mucosa of Pirc rats with spontaneous tumorigenesis. Oxaliplatin or oxaliplatin + 50%HA was administered to Pirc rats from the eighth to the ninth months of age, when colon tumors had already developed. These animals were more sensitive to the general toxicity of oxaliplatin, showing strong anemia, asthenia and weight loss when treated with 2.4 mg kg −1 oxaliplatin daily. For this reason, the treatment was modified to 1.5 mg kg −1 i.p. twice weekly for 4 weeks. As shown in Fig. 6A , Pirc rats showed hypersensitivity to mechanical stimuli (Paw pressure test) starting on week 1 (after two injections) with a continual pain threshold decrease over time.
In parallel, another group of animals underwent a 4-week treatment with oxaliplatin (1.5 mg kg −1 i.p. twice weekly) and 50%HA (300 mg kg −1 p.o. daily starting on the first day of oxaliplatin administration). 50%HA significantly prevented pain development (Fig. 6A) . The week 4 was chosen as optimal for neuropathy establishment and duration of 50%HA treatment. On week 4, Pirc rats (9 months old) were sacrificed and apoptosis was evaluated in colon tumors as well as in the apparently normal mucosa. The treatment with 50%HA did not affect the apoptotic index either in the normal mucosa or in the tumors (Fig. 6B) , demonstrating that 50%HA did not interfere with oxaliplatin's pharmacological effect. In agreement with other authors 25 , the level of apoptosis in tumors was significantly higher than that in normal mucosa.
Discussion
The present data show the anti-neuropathic effects of different Astragali radix extracts in a rat model of oxaliplatin-induced neurotoxicity. In particular, 50%HA controls pain and prevents damage to the peripheral nervous system and the maladaptive changes along the entire nociceptive pathway within the central nervous system. Aqu, 20%HA, and 50%HA significantly reduce the pain sensitivity alterations caused by repeated administrations of the platinum derivative. 50%HA is the most effective, fully preventing hypersensitivity to suprathreshold stimulation (hyperalgesia-related measurement) and pain threshold alterations to stimuli that normally do not provoke pain (allodynia-related measurement). Pain relief was observed after a subchronic treatment, suggesting a neuroprotective mechanism against the damages that result in chronic pain. Accordingly, 50%HA prevents morphological derangements in DRGs, a primary target for oxaliplatin neurotoxicity 19, 26 , as well as the significant increase in ATF-3 expression, a member of the ATF-3/cAMP-responsive element binding protein family considered a selective marker of neuronal damage 19, 20, 27 . Moreover, 50%HA prevents the downregulation of the phosphorylated heavy neurofilament, a parameter indicative of latent axonal damage 19, 28 .
In vitro, we recently described the protective characteristics of 50%HA against the toxicity evoked by oxaliplatin in primary astrocytes 13 . Glial cells have been recognized as powerful modulators of pain 29 . The metabolic activation of microglia and astrocytes participates in the maladaptive plasticity of the central nervous system, facilitating nociceptive processes, generating clinical pain hypersensitivity and making neuropathic pain an autonomous disease state 29 . Despite the limited ability of oxaliplatin to cross the blood brain barrier 30 , we previously observed glial activation induced by oxaliplatin in spinal cord and brain areas differently according to cell type, anatomical region, and treatment time-points 19 . The increased cell density of microglia and astrocytes is strongly related to pain hypersensitivity since the glial inhibitor minocycline and fluorocytrate fully prevent oxaliplatin-evoked pain 21 . The present results reveal an inhibitory effect of 50%HA on microglia and astrocytes (decreasing in the number of both cell types) in the dorsal horn of the spinal cord, in brain areas belonging to the "pain neuromatrix" 31 and in other brain networks involved in somatosensory, motor, attention and emotional processing 32 . To note, 50%HA seems to be able to modulate glial cells instead of acting as a general depressor of glial functions. The homeostatic properties of the Astragalus extract may allow inhibition of glial hyper-reactivity but preserve neuroprotection, a housekeeping role of these cells 33 . Several bioactive compounds have been highlighted in the dried root of Astragalus such as isoflavonoids (calycosin and formononetin), triterpene saponins (whose major component is represented by Astragaloside IV) 34 , polysaccharides, amino butyric acids and various trace elements 15, 35, 36 . The phytochemical characterization of the present extracts reveals the presence of these active compounds, showing similar contents of total saponins in Aqu, 20%HA and 50%HA whereas isoflavones are more concentrated in the hydroalcoholic extracts of Astragali radix rather than in Aqu 13 . Since Astragalus flavonoids, saponins and polysaccharides 15,36,37 possess considerable activities against oxidative imbalance and oxaliplatin induces oxidative damage relevant for pain sensitivity 38 , the mRNA levels of redox-related molecules are studied in different nervous districts. Nrf2 is an important cellular defense response against oxidative or electrophilic stress 39 , it plays an imperative role in inhibiting oxidative stress via upregulating the Nrf2-driven antioxidants, including mainly heme oxygenase 1 (HO-1), NQO1 and γ -glutamate-cysteine ligase (γ -GCL) 40 . In oxaliplatin-treated animals Nrf2 slightly increases in DRGs whereas NQO1 decreases in the spinal cord. 50%HA reduces both Nrf2 and NQO1 levels in DRGs and spinal cord, suggesting the lack of a direct stimulation of the cellular antioxidant machinery. Nevertheless, because of the neuroprotective profile of 50%HA, less need of physiological antioxidant responses after Astragalus administration could be hypothesized. The neuroprotective properties of Astragalus root components have been previously described. Formononetin was able to preserve neurons from apoptosis 41 . Astragaloside IV reduced caspase-3 activation, protected fiber demyelination and promoted peripheral nerve regeneration in animal models of neuropathy 42 . A general restorative property of Astragalus extracts has also been reported: anti-hypertensive and immunomodulatory activities 15 as well as the capability to protect the liver and reduce hyperglycemia 43 . In the present results, histological observations of the liver and kidney also strongly support the hepato-and kidney-protective effect of 50%HA against oxaliplatin-induced organ toxicity.
It is relevant to underline that the efficacy of 50%HA is strongly related to the whole phytocomplex. Aimed to study the role of the different chemical families present in the extract, we have been performed a fractionation by solvents with increasing polarity (dichloromethane, ethyl acetate, butanol and water). The procedure let to the separation of constituents on the basis of their different polarity, namely lipophilic constituents have been solubilized in dichloromethane, the aglycons of saponins and flavonoids and their less polar glycosides in ethyl acetate, saponins and flavonoids glycosides (and all the other polar constituents not completely soluble in water) in butanol. Final water fraction contains only constituents such as simple sugars or polysaccharides. After repeated administrations, none of these fractions show pain relieving properties in oxaliplatin-treated animals. On the contrary, the animals that received the co-administration of all the fractions show a decrease of pain hypersensitivity comparable to that induced by the total crude extract suggesting the synergy of several compounds and validating the traditional phytotherapic approach.
As regards safety against chemotherapy, the lack of interference of Astragalus extract (50%HA) in oxaliplatin-induced caspase-3 activation and cell mortality in the colon cancer cell line HT-29 has been previously reported 13 . In the present study, the possible Astragalus interference with the anticancer activity of oxaliplatin was evaluated in vivo in Pirc rats, a genetic model of colon cancer. This rat strain harbors a heterozygous mutation in Apc, the key gene in colon carcinogenesis. Accordingly, Pirc rats spontaneously develop tumors in both the small and large intestines, mimicking the human pathology 44 . We used this model to ascertain if 50%HA would impede the chemotherapic effect of oxaliplatin on tumors. Apoptosis was measured in the normal mucosa and tumors, and our results indicate that 50%HA does not interfere with oxaliplatin-induced apoptosis in either tissue, thus suggesting that Astragalus does not modify the anticancer efficacy of the platinum derivative.
On the other hand, compelling evidence suggests the usefulness of Astragali radix in cancer treatment. Astragalus is included among the specific plants that contribute to tumor response when combined with oxaliplatin-based chemotherapy for colorectal cancer 17 . The combination of Chinese herbal medicine, including Astragali radix, improved the effectiveness of FOLFOX against advanced colon cancer in terms of tumor response rate and one-year survival. Patients also reported fewer adverse effects and experienced better quality of life 16 . A metanalysis of randomized trials concluded that Astragalus-based treatment increased the efficacy (by improving survival, tumor response, and performance status) and reduced the toxicity of standard platinum-based treatment in patients affected by advanced non-small-cell lung cancer 45 . Anticancer properties were suggested for Astragaloside IV which exhibited in vivo anticancer activity and enhanced immune response 46 . Astragalus saponins inhibited proliferation in a human colorectal cancer HT-29 cell line regardless of the p53 status, demonstrating tumor suppressive effects in a nude mice xenograft model and enhancing the cytotoxic effect of 5-FU 47 . Cui et al. highlighted the anti-tumoral activity of Astragalus membranaceus in counteracting hepatocarcinogenesis in rats 48 . Astragalus polysaccharides have demonstrated to have anti-proliferative effects in cell-line studies 49 .
Conclusions
Since improved cancer therapy has led to increased life expectancy and cure rates in most types of cancers, the issue of symptom management has begun to play a very important role 6 . Pain is a prominent under-treated symptom in cancer 50 ; no effective agents are available for the treatment of chemotherapy-induced neuropathy 8 . The Astragali radix hydroalcoholic extract 50%HA was able to control oxaliplatin-induced pain and prevent alterations in both the peripheral and central nervous system. 50%HA may offer a dual protective approach against etiological factors and resulting maladaptive plasticity without altering the anticancer efficacy of oxaliplatin.
Methods
Plant material, sample preparation and analysis. A commercial sample (0.5 kg dry herbal drug) of Astragali radix (Huang Qi) was purchased from Gansu China Shenzhen Green Nature Co. LTD. The Art. No. was 30 237, China production lot no. 0061, July 2010. The plant material was comminuted, reduced to a powder form, and used to make the extracts. The decoction (Aqu) was prepared using 5 g of the herbal drug plus 100 mL distilled water and boiled for 4 h on a heating plate (adding water when necessary to maintain a constant volume). After 4 h of boiling, the decoction was cooled down to room temperature on a horizontal shaker to improve the bottom deposition of the solid drug. It was then filtered and centrifuged (5000 rpm, Δ t = 10 min, temp. = 20 °C), and after that, the extract was frozen (− 24 °C) and lyophilized.
The 20%HA extract was prepared with 5 g of the herbal drug plus 25 mL of EtOH 80%. The mixture was left under horizontal shaking at room temperature (25 °C) for 2 days, filtered, and extracted twice. Solutions were combined, concentrated under low pressure to eliminate EtOH, frozen (− 24 °C), and lyophilized.
The 50% hydroalcoholic dried extract (50%HA) Axtragyl ™ was purchased from Giellepi S. p. A. Health Science Division. The extract was reported to contain 30% maltodextrins as eccipients.
For the quantitative HPLC analysis, the following standards were used: Astragaloside IV, European Pharmacopoeia (EP) reference standard (97.8%) and formononetin ( ≥99% by HPLC) from Sigma-Aldrich. Dextrans with increasing and defined molecular weights (5000, 150 000, 270 000, 670 000 Da) were from Sigma-Aldrich. The full characterization of the Astragalus extracts has been previously published 13 . Subsequently, 50%HA was fractioned using solvents with increasing polarity. The crude extract was suspended in water and extracted with 1) dichloromethane, 2) ethyl acetate and 3) butanol. Dried extracts were obtained by evaporation of dichloromethane, ethyl acetate and buthanol, using a rotary evaporator in vacuum under reduced pressure at 40 °C, or by freezing and lyophilization of the water fraction. The dried weight of the single fractions compared to the quantity of the total extract was: 1) dichloromethane fraction, 22%; 2) ethyl acetate fraction, 3%; 3) butanol fraction, 6%; 4) water fraction, 69%. Oxaliplatin model. SD rats were treated with 2.4 mg kg −1 oxaliplatin, administered i.p. for 5 consecutive days every week for 3 weeks (15 i.p. injections) 52 . Oxaliplatin was dissolved in 5% glucose solution. The model used for the present research is consistent with the clinical practice. The dose of 2.4 mg kg −1 oxaliplatin corresponds to the common human dosage (considering the Km factor 37 for the conversion of animal doses to the Human Equivalent Dose). The daily repeated administration of 2.4 mg kg −1 performed in the animal model provides a cumulative dose of 36 mg kg −1 corresponding to 1332 mg/m 2 . This dosage mimics the clinical cumulative oxaliplatin dose causing chronic neuropathy. The inorganic platinum plasmatic level on day 21 is 3.573 ± 0.217 μ g/mL in our conditions, in line with human plasma concentrations 53 . Control animals received an equivalent volume of 5% glucose i.p. Behavioral and biochemical tests were performed on day 21. In the experiment with Pirc rats, 9 female Pirc rats, aged 8 months were randomly allocated to oxaliplatin treatment (n = 4) or to the same treatment with 50%HA (n = 5). Oxaliplatin treatments of Pirc rats were set up considering the higher sensitivity to oxaliplatin toxicity of these animals in comparison to SD rats. The dose of 1.5 mg kg −1 was injected i.p. twice a week for 4 weeks till the full development of painful neuropathy.
Animals.
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Extract treatments. The extracts, Aqu, 20%HA and 50%HA, were suspended in 1% carboxy methyl cellulose (CMC) and administered p.o. every day for 3 weeks to SD rats. Aqu and 20%HA were administered at 300 mg kg −1 whereas 50%HA was administered in a dose range of 30 to 300 mg kg −1 . The fractions obtained from 50%HA were administered as follows: 1) dichloromethane fraction, 66 mg kg −1 ; 2) ethyl acetate fraction, 9 mg kg −1 ; 3) butanol fraction, 18 mg kg −1 ; 4) water fraction, 207 mg kg −1 . These doses were obtained considering the weight percent of the fractions (22%, 3%, 6% and 69% for fractions 1-4, respectively) compared to the quantity of the total extract and referred to the total extract dose of 300 mg kg −1 . Extracts, or fractions, were orally administered every day for 3 weeks starting from the first day of oxaliplatin administration.
Pirc rats were treated with 300 mg kg −1 50%HA p.o. daily for 4 weeks starting from the first day of oxaliplatin administration. Behavioral evaluations were performed 24 h after the last injection when not otherwise specified.
Paw pressure test. The nociceptive threshold in the rat was determined by an analgesimeter (Ugo Basile, Varese, Italy) as previously described 19 and reported in detail in the supplementary material (Supplementary Methods).
Von Frey test. An electronic Von Frey hair unit (Ugo Basile, Varese, Italy) was used according to a previously described method 19 and reported in detail in the supplementary material (Supplementary Methods).
Cold plate test. The Cold plate apparatus was used according to a previously described method 19 . The temperature of the cold plate was kept constant at 4 °C ± 1 °C. The method is reported in detail in the supplementary material (Supplementary Methods).
Sciatic nerves examination. On day 21, at the end of the last behavioral test session, SD rats belonging to each group were sacrificed under general anesthesia and ipsilateral sciatic nerves were fixed, dehydrated and infiltrated with paraffin (Diapath, Milan, Italy). Sectioned tissues were evaluated immunohistochemically for p-NF-H as reported 19 . For details, see the supplementary material (Supplementary Methods).
L4-L5 DRG examination. SD rat lumbar dorsal root ganglia were subjected to the treatment described for the sciatic nerves, sectioned, and stained using the Azan-Mallory method as previously reported 19 . The ATF-3 expression in L4-L5 DRGs was evidenced by the use of an anti-ATF-3 primary antisera (rabbit anti-ATF-3, 1:500; Santa Cruz Biotechnology), evidenced with diaminobenzidine as reported 19 . For details, see the supplementary material (Supplementary Methods).
Immunohistochemistry of spinal cord and brain glia. On day 21, SD rats were sacrificed, the L4/L5 segments of the spinal cord were exposed from the lumbovertebral column via laminectomy and identified by tracing the dorsal roots from their respective DRG. The brains were removed, sliced in coronal sections and areas of interest were identified using Paxinos and Watson's atlas (Paxinos and Watson, 1982) . Quantification of the number and morphology of Iba1 immunoreactive microglia (rabbit, 1:1000; Wako Chemicals, Richmond, USA) and GFAP immunoreactive astrocytes (mouse, 1:5000; Chemicon, Temecula, USA) in the superficial dorsal horns of the spinal cord and in brain areas were performed in four cryostat sections (20 μ m) by a previously reported method 19, 21 . For details see the supplementary material (Supplementary Methods).
mRNA level analysis. The sciatic nerve, L4-L5 DRGs and spinal cord of SD rats (day 21) were collected as described above. mRNA was extracted using TRI -Reagent© (Sigma Aldrich, Milan, Italy). cDNA was obtained using the iScript cDNA Synthesis Kit ® (Bio Rad, Milan, Italy) according to the manufacturer's protocol. Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) mRNA (GenBank accession number: NM_031789.2) was amplified using the following rat gene specific primers: forward: 5′ TGA CTC TGA CTC CGG CAT TTC 3′, reverse 5′ TCC ATT TCC GAG TCA CTG AAC 3′. NQO1 (NAD(P)H dehydrogenase, quinone 1) mRNA (GenBank accession number: NM_017000.3) was amplified using the following rat gene specific primers: forward: 5′ TCA TTT GGG CAA GTC CAT TCC 3′, reverse 5′ TGA GCA ATT CCC TCC TGC CCT 3′. 18 S ribosomal RNA (GenBank accession number: NR_046237.1) was considered as housekeeping gene and amplified using: forward: 5′ TAC CAC ATC CAA GGA AGG CAG CA 3′, reverse 5′ TGG AAT TAC CGC GGC TGC TGG CA 3′. Both sequences were amplified by GoTaq ® Flexi DNA Polymerase 2,500 U (Promega, Milan, Italy). The amplicons were electrophoresed in 1.8% agarose gel containing ethidium bromide. The resultant bands were then quantified by densitometry and the intensity of the signal normalized to18S, thus correcting for any possible uneven loading of RNA.
Liver and kidney histopathological examination. The liver and kidney (SD rats, day 21) were removed, cut into small pieces, and fixed in 10% neutral buffered formalin. After dehydration in gradual ethanol (50% to 100%), they were cleared in xylene and embedded in paraffin. Sections (5 μ m thick) were stained with hematoxylin and eosin dye and observed under a light microscope at an original magnification of 20X and 40X.
Determination of apoptosis in colon tumors and normal colon of Pirc rats. After the 4-week treatments (described above), apoptosis was evaluated in paraffin-embedded sections (4 μ m thick) of normal colonic mucosa and tumors stained with hematoxylin-eosin, as reported 54 . At least 15 full longitudinal crypt sections of normal mucosa/rat were scored at the microscope, determining the presence of cells in each crypt with the following characteristics of apoptosis: cell shrinkage, loss of normal contact with the adjacent cells of the crypt, chromatin condensation or formation of round or oval nuclear fragments ("apoptotic bodies"). When clusters of more than one apoptotic body were seen within the diameter of one cell, these bodies were considered as fragments of one apoptotic cell. Tumor apoptosis was determined by scoring at least 500 cells/tumor for the presence of Scientific RepoRts | 7:42021 | DOI: 10.1038/srep42021 apoptotic cells that were coded as described above. In tumors and colon mucosa, apoptosis was scored by a single observer on coded samples and quantified as apoptotic index (AI = number of apoptotic cells/cells scored × 100).
Statistical analysis.
Behavioral measurements were performed on 10 rats for each treatment carried out in 2 different experimental sets. Results were expressed as means ± S.E.M. and the analysis of variance was performed by one-way ANOVA. A Bonferroni's significant difference procedure was used as post-hoc comparison. One-way ANOVA followed by Bonferroni post-test were used for the mRNA level analysis of comparisons between groups. Histologic, morphometric, and immunohistochemical analyses were performed on 6 rats per group, evaluating 6 sciatic nerves, 6 L4-L5 DRGs, and 6 spinal cord sections for each animal. DRG values are reported as means of L4 and L5. One-way repeated-measures analysis of variance followed by the Student-Newman-Keuls post hoc test was used to compare the percentage of ATF-3-positive neurons in small, medium, and large neurons in L4-L5 DRGs of oxaliplatin-treated rats. Histological studies of Pirc rats were analyzed by the t-test. For the rest of the comparisons, a Mann-Whitney test was used.
In all experimental procedures, the investigators were blind to the experimental status of each animal. In addition, all images were captured and analyzed by an investigator other than the one who took measurements to avoid possible bias. Data were analyzed using the "Origin 9" software (OriginLab, Northampton, MA). Differences were considered significant at a P < 0.05.
